Mylan Beats Sanofi On Lantus Patent

Company Ready To Launch Insulin Glargine Upon FDA Approval

 
• By Akriti Seth
  
Generate a summary of this article
Listen to this article
Beta

A US district court has ruled in favor of Mylan in a dispute with Sanofi over a Lantus SoloStar device patent, with the patent protecting the insulin glargine injector pen found to be invalid and not infringed. Mylan, along with partner Biocon, expects to launch its Semglee version mid-year, following FDA approval.

Lantus
A Lantus SoloStar device patent has been found not infringed and invalid for lack of written description • Source: Shutterstock

A US district court in New Jersey has ruled in Mylan’s favor as part of a dispute with Sanofi over its Lantus SoloSTAR (insulin glargine) device. The court found that claims of US device patent 9,526,844, asserted by Sanofi against Mylan’s Semglee insulin glargine product and Vystra device, were not infringed and were invalid for lack of written description. However, the court found that Mylan had failed to demonstrate that the patent was invalid for obviousness.

Specifically, the district court was not persuaded by Sanofi’s argument that Mylan’s Vystra device infringed a limitation contained in claim...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By Nabil

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By Akriti Seth

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By David Wallace

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin